MARY CASE: Open Payments
NPI 1184695223 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,351 in 67 payments from 33 companies in 2025. Trend: 2023 $1,249 · 2024 $1,262 · 2025 $1,351
Food & beverage: $1,351
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 5 | $115 |
| Exelixis Inc. | 5 | $108 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| Daiichi Sankyo Inc. | 3 | $76 |
| PFIZER INC. | 4 | $73 |
| ABBVIE INC. | 4 | $72 |
| Incyte Corporation | 3 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Janssen Biotech, Inc. | 3 | $58 |
| Alexion Pharmaceuticals, Inc. | 3 | $56 |
Products named: CABOMETYX, KEYTRUDA, REBLOZYL, ULTOMIRIS, BRUKINSA, Tibsovo, Enhertu, Lenvima.
Industry payments across LA — which companies pay providers there.
